Publication
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson, Karen J. Scott, David Taggart, Emma J. West, Erica Wilson, Gerard J. Nuovo, Simon Thomson, Robert Corns, Ryan K. Mathew, Martin J. Fuller, Timothy J. Kottke, Jill M. Thompson, Elizabeth J. Ilett, Julia V. Cockle, Philip van Hille, Gnanamurthy Sivakumar, Euan S. Polson, Samantha J. Turnbull, Elizabeth S. Appleton, Gemma Migneco, Ailsa S. Rose, Matthew C. Coffey, Deborah A. Beirne, Fiona J. Collinson, Christy Ralph, D. Alan Anthoney, Christopher J. Twelves, Andrew J. Furness, Sergio A. Quezada, Heiko Wurdak, Fiona Errington-Mais, Hardev Pandha, Kevin J. Harrington, Peter J. Selby, Richard G. Vile, Stephen D. Griffin, Lucy F. Stead, Susan C. Short, Alan A. Melcher
Science Translational Medicine, January 2018, American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.aam7577